|
1
|
Nigg EA: Mitotic kinases as regulators of
cell division and its checkpoints. Nat Rev Mol Cell Biol. 2:21–32.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Carmena M and Earnshaw WC: The cellular
geography of aurora kinase. Nat Rev Mol Cell Biol. 4:842–854. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Warner SL, Bearss DJ, Han H and von Hoff
DD: Targeting aurora-2 kinase in cancer. Mol Cancer Ther.
2:589–595. 2003.PubMed/NCBI
|
|
4
|
Fukushige S, Waldman FM, Kimura M, Abe T,
Furukawa T, Sunamura M, Kobari M and Horii A: Frequent gain of copy
number on the long arm of chromosome 20 in human pancreatic
adenocarcinoma. Genes Chromosomes Cancer. 19:161–169. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Isola JJ, Kallioniemi OP, Chu LW, Fuqua
SA, Hilsenbeck SG, Osborne CK and Waldman FM: Genetic aberrations
detected by comparative genomic hybridization predict outcome in
node-negative breast cancer. Am J Pathol. 147:905–911.
1995.PubMed/NCBI
|
|
6
|
Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW,
Sahin A, Brinkley BR and Sen S: Tumor amplification kinase
STK15/BTAK induces centrosome amplification, aneuploidy and
transformation. Nat Genet. 20:189–193. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bischoff JR, Anderson L, Zhu Y, Mossie K,
Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C,
Chan CS, Novotny M, Slamon DJ and Plowman GD: A homologue of
Drosophila aurora kinase is oncogenic and amplifies in human
colorectal cancers. EMBO J. 17:3052–3065. 1998.PubMed/NCBI
|
|
8
|
Drucker BJ: Renal cell carcinoma: current
status and future prospects. Cancer Treat Rev. 31:536–545. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bodmer D, van den Hurk W, van Groningen
JJ, Eleveld MJ, Martens GJ, Weterman MA and van Kessel AG:
Understanding familial and non-familial renal cell cancer. Hum Mol
Genet. 11:2489–2498. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kurahashi T, Miyake H, Hara I and Fujisawa
M: Significance of Aurora-A expression in renal cell carcinoma.
Urol Oncol. 25:128–133. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Miyake H, Nelson C, Rennie PS and Gleave
ME: Overexpression of insulin-like growth factor binding protein-5
helps accelerate progression to androgen-independence in the human
prostate LNCaP tumor model through activation of
phosphatidylinositol 3′-kinase pathway. Endocrinology.
141:2257–2265. 2000.PubMed/NCBI
|
|
12
|
Miyake H, Hara I, Kurahashi T, Inoue TA,
Eto H and Fujisawa M: Quantitative detection of micrometastases in
pelvic lymph nodes in patients with clinically localized prostate
cancer by real-time reverse transcriptase-PCR. Clin Cancer Res.
13:1192–1197. 2007. View Article : Google Scholar
|
|
13
|
Miyake H, Yamanaka K, Muramaki M, Hara I
and Gleave ME: Therapeutic efficacy of adenoviral-mediated p53 gene
transfer is synergistically enhanced by combined use of antisense
oligodeoxynucleotide targeting clusterin gene in a human bladder
cancer model. Neoplasia. 7:171–179. 2005. View Article : Google Scholar
|
|
14
|
Tanaka E, Hashimoto Y, Ito T, Okumura T,
Kan T, Watanabe G, Imamura M, Inazawa J and Shimada Y: The clinical
significance of Aurora-A/STK15/BTAK expression in human esophageal
squamous cell carcinoma. Clin Cancer Res. 11:1827–1834. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gritsko TM, Coppola D, Paciga JE, Yang L,
Sun M, Shelley SA, Fiorica JV, Nicosia SV and Cheng JQ: Activation
and overexpression of centrosome kinase BTAK/Aurora-A in human
ovarian cancer. Clin Cancer Res. 9:1420–1426. 2003.PubMed/NCBI
|
|
16
|
Guan Z, Wang XR, Zhu XF, Huang XF, Xu J,
Wang LH, Wan XB, Long ZJ, Liu JN, Feng GK, Huang W, Zeng YX, Chen
FJ and Liu Q: Aurora-A, a negative prognostic marker, increases
migration and decreases radiosensitivity in cancer cells. Cancer
Res. 67:10436–10444. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu X, Shi Y, Woods KW, Hessler P, Kroeger
P, Wilsbacher J, Wang J, Wang JY, Li C, Li Q, Rosenberg SH, Giranda
VL and Luo Y: Akt inhibitor a-443654 interferes with mitotic
progression by regulating aurora a kinase expression. Neoplasia.
10:828–837. 2008.PubMed/NCBI
|
|
18
|
Cha TL, Chuang MJ, Wu ST, Sun GH, Chang
SY, Yu DS, Huang SM, Huan SK, Cheng TC, Chen TT, Fan PL and Hsiao
PW: Dual degradation of aurora A and B kinases by the histone
deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of
renal cancer cells. Clin Cancer Res. 15:840–850. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou J and Giannakakou P: Targeting
microtubules for cancer chemotherapy. Current Med Chem. 5:665–671.
2005.
|
|
20
|
Mazumdar A, Henderson YC, El-Naggar AK,
Sen S and Clayman GL: Aurora kinase A inhibition and paclitaxel as
targeted combination therapy for head and neck squamous cell
carcinoma. Head Neck. 31:625–634. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tanaka E, Hashimoto Y, Ito T, Kondo K,
Higashiyama M, Tsunoda S, Ortiz C, Sakai Y, Inazawa J and Shimada
Y: The suppression of aurora-A/STK15/BTAK expression enhances
chemosensitivity to docetaxel in human esophageal squamous cell
carcinoma. Clin Cancer Res. 13:1331–1340. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee HH, Zhu Y, Govindasamy KM and Gopalan
G: Downregulation of Aurora-A overrides estrogen-mediated growth
and chemoresistance in breast cancer cells. Endocr Relat Cancer.
15:765–775. 2008. View Article : Google Scholar : PubMed/NCBI
|
